Author: Charlotte Russell
Nicotinamide Riboside (NR) Study Paper published in Genome Medicine
Posted /Interesting findings from the NR Study carried out by the MitoCAMB Research group were published last week in Genome Medicine on ‘Effects of nicotinamide riboside in mitochondrial DNA disease’. This small pilot study investigated whether nicotinamide riboside (NR), a form of vitamin B3, could improve mitochondrial function in people with mitochondrial disease. NR was found to […]
Cambridge to lead new £50 million centre to study mitochondrial DNA diseases
Posted /The Medical Research Council (MRC) has announced a £50 million investment in the new MRC Centre of Research Excellence in Mitochondrial Genome Therapeutics, which aims to enable new treatments into potentially fatal mitochondrial DNA diseases. LifeArc Centre for Rare Mitochondrial Disease and MitoCAMB are incredibly excited to share that our very own WP3 Co-Lead Prof Michal […]